Table 1.
Patient characteristics.
| All Patients | Patients with Grade III | Patients with Grade IV | |
|---|---|---|---|
| No. of patients | 355 | 40 | 315 |
| Age at diagnosis, years a | 56 (45–65) | 35 (31–46) | 58 (48–66) |
| Females | 114 (32.1) | 14 (35.0) | 100 (31.7) |
| Males | 241 (67.9) | 26 (65.0) | 215 (68.3) |
| Grade: b | 40 (11.3) | 315 (88.7) | |
| PS: | |||
| 0 | 190 (53.5) | 22 (55.0) | 168 (53.3) |
| 1 | 120 (33.8) | 13 (32.5) | 107 (34.0) |
| 2 | 39 (11.0) | 5 (12.5) | 34 (10.8) |
| 3 | 6 (1.7) | 0 (0.0) | 6 (1.9) |
| Surgery | |||
| Non-radical | 105 (29.6) | 10 (25.0) | 95 (30.2) |
| Radical | 250 (70.4) | 30 (75.0) | 220 (69.8) |
| Analyzed tissue: | |||
| Diagnosis | 301 (84.8) | 30 (75.0) | 271 (86.0) |
| Recurrence | 54 (15.2) | 10 (25.0) | 44 (14.0) |
| MGMT status: c | |||
| Unmethylated | 139 (46.3) | 2 (9.1) | 137 (493) |
| Methylated | 161 (53.7) | 20 (90.9) | 1412 (50.7) |
| IDH status: d | |||
| Wild type | 267 (84.8) | 9 (29.2) | 258 (91.2) |
| Mutated | 48 (15.2) | 23 (71.8) | 25 (8.8) |
| PD-L1 expression: e | |||
| 0% | 99 (66.0) | 19 (100.0) | 80 (61.1) |
| >0% | 51 (34.0) | 0 (0.0) | 51 (38.9) |
| MMR protein expression: | |||
| Retained | 312 (87.9) | 27 (67.5) | 285 (90.5) |
| Partial loss | 28 (7.9) | 9 (22.5) | 19 (6.0) |
| Complete loss | 15 (4.2) | 4 (10.0) | 11 (3.5) |
Data expressed as n (%) or a median (IQR). b Grade III included 31 anaplastic astrocytoma, 2 Anaplastic ependymoma, 1 anaplastic ganglioneuronal tumor, and 6 anaplastic oligodendroglioma, while all grade IV were glioblastoma. Data not available in c 55, d 40, and e 205 patients.